Institution profile

医療法人喜和会 喜多村クリニック

Explore the institution's name, address and registered technologies as published, along with plan classifications, score components and sources.

The ranking reflects only the registration data published by Japan's Ministry of Health, Labour and Welfare; it does not represent treatment outcomes or quality of care. Scoring method →

Source: Ministry of Health, Labour and Welfare public directory of regenerative medicine providers MHLW e-Regenerative Medicine public register · Directory archive date I: 2026-07-19 / II: 2026-09-26 / III: 2026-05-18 · Internet Archive

MHLW e-Regenerative Medicine public registerPublic document number 02G2504023 +2

Location

Prefecture
Fukuoka
Address
大野城市錦町4-3-8-101

Plan classification

  • Class INot registered
  • Class IINot registered
  • Class IIIThe low-risk category under the law.

Certified committee for regenerative medicine

  • 同仁会認定再生医療等委員会
  • 日本薬事法務学会再生医療等委員会

Public score

29.5/ 100

A · Review level
10.0 / 30
B · Technologies
15.9 / 35
C · Coverage
3.6 / 25
D · Class I / II technologies
0.0 / 10

The public score is calculated from public registration information and does not reflect quality of care. Scoring method →

Overall ranking

No. 1636of 1736

Registered technologies
3
Areas covered
1

Technology areas · Rank

Position in the overall score distribution

0–100 · Public score
000–9.9 · 0 institutions
01010–19.9 · 0 institutions
2172020–29.9 · 217 institutions
3163030–39.9 · 316 institutions
7564040–49.9 · 756 institutions
2465050–59.9 · 246 institutions
1326060–69.9 · 132 institutions
417070–79.9 · 41 institutions
248080–89.9 · 24 institutions
49090–100 · 4 institutions
This institution 29.5
Public score →100

Registered technologies (3)

NK and immune cells 3
Registered technologies · Japanese originalTechnology areasPlan classification
がんの治療、再発・転移予防、発がん予防のための自己免疫細胞を用いた免疫細胞療法(6種複合免疫療法)NK and immune cellsClass III
成分採血での悪性腫瘍の抑制及び治療のためのGMP準拠Alpha-GalactosylceramideとCD1d抗原提示自己樹状細胞を用いたNKT細胞標的治療(RIKEN-NKT®)NK and immune cellsClass III
全血採血での悪性腫瘍の抑制及び治療のためのGMP準拠Alpha-GalactosylceramideとCD1d抗原提示自己樹状細胞を用いたNKT細胞標的治療(RIKEN-NKT®Ⅱ)NK and immune cellsClass III

Certified committee for regenerative medicine

  • 同仁会認定再生医療等委員会
  • 日本薬事法務学会再生医療等委員会

Public document number

  • 02G2504023
  • 02G2601002
  • 02G2601003
Plan classification · Certified committee for regenerative medicine · Public document number
Registered technologiesPlan classificationCertified committee for regenerative medicinePublic document number
がんの治療、再発・転移予防、発がん予防のための自己免疫細胞を用いた免疫細胞療法(6種複合免疫療法)Class III同仁会認定再生医療等委員会02G2504023
全血採血での悪性腫瘍の抑制及び治療のためのGMP準拠Alpha-GalactosylceramideとCD1d抗原提示自己樹状細胞を用いたNKT細胞標的治療(RIKEN-NKT®Ⅱ)Class III日本薬事法務学会再生医療等委員会02G2601002
成分採血での悪性腫瘍の抑制及び治療のためのGMP準拠Alpha-GalactosylceramideとCD1d抗原提示自己樹状細胞を用いたNKT細胞標的治療(RIKEN-NKT®)Class III日本薬事法務学会再生医療等委員会02G2601003

Other institutions in the same prefecture

← Institution directory
One-to-one advice

Still unsure? Ask an advisor

Use the “Chat with an advisor” button on this page (at the bottom of the screen on mobile, bottom right on desktop) to open a chat with the Stem Cell Japan advice desk. Consultation and coordination are free, and an advisor replies within one working day.

Chat with an advisor